Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
<p dir="ltr">The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CM...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513566114054144 |
|---|---|
| author | Mohamad Y. Khatib (11659459) |
| author2 | Karimulla S. Shaik (14777197) Amna A. Ahmed (14777200) Mohammad A. Alwraidat (14777203) Ahmed S. Mohamed (11659456) Mohamad R. Abou Kamar (14777206) Mouhammad Z. Sharaf Eldean (14777209) Bashar K. Aldaraiseh (14777212) Abdulqadir J. Nashwan (11659453) |
| author2_role | author author author author author author author author |
| author_facet | Mohamad Y. Khatib (11659459) Karimulla S. Shaik (14777197) Amna A. Ahmed (14777200) Mohammad A. Alwraidat (14777203) Ahmed S. Mohamed (11659456) Mohamad R. Abou Kamar (14777206) Mouhammad Z. Sharaf Eldean (14777209) Bashar K. Aldaraiseh (14777212) Abdulqadir J. Nashwan (11659453) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamad Y. Khatib (11659459) Karimulla S. Shaik (14777197) Amna A. Ahmed (14777200) Mohammad A. Alwraidat (14777203) Ahmed S. Mohamed (11659456) Mohamad R. Abou Kamar (14777206) Mouhammad Z. Sharaf Eldean (14777209) Bashar K. Aldaraiseh (14777212) Abdulqadir J. Nashwan (11659453) |
| dc.date.none.fl_str_mv | 2020-11-12T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/ccr3.3487 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Tocilizumab_induced_cytomegalovirus_colitis_in_a_patient_with_COVID_19/22257565 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Immunology CMV reactivation Gastrointestinal bleeding Intestinal perforation Tocilizumab Immunosuppressive therapy COVID-19 |
| dc.title.none.fl_str_mv | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/ccr3.3487" target="_blank">http://dx.doi.org/10.1002/ccr3.3487</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_f8de49860a2e51ede8940e3514205e2b |
| identifier_str_mv | 10.1002/ccr3.3487 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22257565 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19Mohamad Y. Khatib (11659459)Karimulla S. Shaik (14777197)Amna A. Ahmed (14777200)Mohammad A. Alwraidat (14777203)Ahmed S. Mohamed (11659456)Mohamad R. Abou Kamar (14777206)Mouhammad Z. Sharaf Eldean (14777209)Bashar K. Aldaraiseh (14777212)Abdulqadir J. Nashwan (11659453)Biomedical and clinical sciencesClinical sciencesImmunologyCMV reactivationGastrointestinal bleedingIntestinal perforationTocilizumabImmunosuppressive therapyCOVID-19<p dir="ltr">The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/ccr3.3487" target="_blank">http://dx.doi.org/10.1002/ccr3.3487</a></p>2020-11-12T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/ccr3.3487https://figshare.com/articles/journal_contribution/Tocilizumab_induced_cytomegalovirus_colitis_in_a_patient_with_COVID_19/22257565CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222575652020-11-12T03:00:00Z |
| spellingShingle | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 Mohamad Y. Khatib (11659459) Biomedical and clinical sciences Clinical sciences Immunology CMV reactivation Gastrointestinal bleeding Intestinal perforation Tocilizumab Immunosuppressive therapy COVID-19 |
| status_str | publishedVersion |
| title | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| title_full | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| title_fullStr | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| title_full_unstemmed | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| title_short | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| title_sort | Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19 |
| topic | Biomedical and clinical sciences Clinical sciences Immunology CMV reactivation Gastrointestinal bleeding Intestinal perforation Tocilizumab Immunosuppressive therapy COVID-19 |